Marcio Machado Dias Ferreira

Lead the Iberia (Spain and Portugal) cluster and it's commercial operations for Vertex Pharmaceuticals to achieve business objectives for marketed products and launch multiple new innovative medicines. Responsible for managing the P&L, securing market access for new and marketed medicines, and leading the overall organization for Vertex in cystic fibrosis (CF), hematology (SCD/TDT), as well as future therapeutic areas.

Responsible for the execution of Vertex's market access strategies and key tactics in Spain and Portugal Lead best-in-class reimbursement negotiations and market access excellence to promote rapid uptake access to the Company's products Manage adaptation of global value dossiers and economic models to meet country-specific Health Technology Assessment (HTA) processes/requirements and communicating these to healthcare authorities

Develop affiliate market access function, instill a culture of excellence and build key capabilities to meet the current and future market access needs Plan and management of market access and pricing activities for in-line and launch products for the Spanish market Lead the strategies and/or development of reimbursement/value dossiers for the National Reimbursement Authority and other stakeholders Develop/implement economic analyses and management of regular reference pricing reviews Build strong relationships with thought leaders, payers, policymakers and healthcare officials

Lead pricing and reimbursement strategy and positioning for pipeline and inline products for the Latin America region. Facilitate local market access product planning and readiness. Define analytical approaches for local and regional Health Technology Assessment (HTA). Foster further areas of opportunities to expand market access in the region. Develop regional outcomes research and support the development of scientific publications.

Design and management of local pharmacoeconomic analyses and outcomes research. Mathematical modelling, piggyback pharmacoeconomic trials and cost-of-illness studies. Product portfolio strategic/value-based pricing and pipeline early-stage of development pricing assessments. Delivery of robust, customized pharmacoeconomic value messages to payors to inform optimal health decision-making. Development of health technology assessment dossiers targeting Federal, State and Municipal product reimbursement. Creation of pharmacoeconomic tools for market access action plans.

Teaching and evaluation of half-year course entitled "Pharmacy Practice Research” (PHM425) for 4th year pharmacy undergraduate students at the Leslie Dan Faculty of Pharmacy.

Design and development of pharmacoeconomic analysis (macro and micro). Design and application of methods for pharmacoepidemiology and related fields. Incidence and prevalence studies, disease patterns, drug utilization studies. Health outcomes such as morbidity, success rates, adverse events, mortality, costs, quality of life, and patient adherence.